Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.
Covered Companies
Covered Companies
Series
CEO Connect
Featuring: CNS Pharmaceuticals
July 09, 2025
John Climaco, CEO of CNS Pharmaceuticals provides an overview of CNSP’s lead program, TPI 287, and discusses key insights from his recent attendance at the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.
What This Means
Featuring: Akari Therapeutics
June 25, 2025
Abizer Gaslightwala, President and CEO of Akari Therapeutics discusses the Company’s recently issued India Patent No. 562,919 titled, “Thailanstatin Analogs,” covering claims for its potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers and ADC technology which has applications across various cancer targets.
KOL Connect
Featuring: CNS Pharmaceuticals
June 24, 2025
Dr. Erin Dunbar, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, discusses the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma’s lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.
What This Means
Featuring: Moleculin Biotech
June 18, 2025
Walter Klemp, Founder, President, CEO and Chairman of Moleculin, discussed the Company’s recently announced positive FDA feedback received on the Pediatric Study Plan for Annamycin in children with relapsed/refractory acute myeloid leukemia (R/R AML).
What This Means
Featuring: Senti Bio
June 18, 2025
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
What This Means
Featuring: Moleculin
June 11, 2025
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
Past Events
New to Virtual Investor
Closing Bell
Closing Bell
Live What This Means
Closing Bell Series
Live What This Means
Closing Bell Series
Closing Bell Series
Closing Bell Series
Closing Bell Series
Past Events
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact